Gene researchers discover fertile Utah
Large families willing to submit DNA for analysis, existing genetics research and other elements position the state highly in predictive and personalized medicine — fields looking at the probability of future health problems based on genetic information and tailoring therapy based on a person's genetic makeup — the experts said at a "technology@breakfast" meeting at the Wells Fargo Center.
"Utah families present a really unique resource for this work," said Dr. Kevin Flanigan, a neurologist and adjunct associate professor of human genetics at the University of Utah's Eccles Institute of Human Genetics. "Researchers here, both academic and in the commercial world, have long experience in using these to advance medical knowledge, and I think one key thing is . . . this knowledge is now being translated back into critical trials, which have potential benefits to our patients."
Michael Paul, president and chief operating officer of LineaGen Research Corp., said discovering molecular "biomarkers" will help guide physicians to more effective treatments.
"We have an integrated personalized medicine content platform — genealogy-based population records, the Utah population database, comprehensive medical records — linked to the types of clinics that Kevin runs, these patient-oriented research clinics. This is really an unmatched platform for biomarker discovery."
Paul also called Utah researchers "the New York Yankees of gene cloning."
"(In) no other place in the world have people identified more disease-causing genes than Utah," he said.
But Jerry Lanchbury, executive vice president of research at Myriad Genetics, noted a potential weakness in basing research on Utahns.
"One of the strengths of the United States is the diversity of the population," he said. "Physicians have to treat a diversity of ethnic groups. Since Utah is a very nondiverse collection of individuals, I think there is actually strengths and weakness here, that the discoveries that are made in Utah have to be validated in other populations."
Lars Mouritsen, chief scientific officer at Sorenson Genomics, said personalized medicine will be needed to reduce drug failures and drug misinteractions. He, too, mentioned genealogy records, research and a willing patient population among Utah's strengths. But all stakeholders need to be more focused on work going on among themselves, he said.
You can be the first to comment on this story.